Bristol Myers suspends mid-stage trial of hepatitis C drug

By Admin
Global bio-pharmaceutical company Bristol Myers Squibb Co has suspended a mid-stage trial of an experimental hepatitis C drug it secured in its $2.5 bi...

Global bio-pharmaceutical company Bristol Myers Squibb  Co has  suspended a mid-stage trial of an experimental hepatitis C drug  it secured in its $2.5 billion buyout of Inhibitex Inc after one patient  developed heart failure.

 The New York-based drug maker said it has suspended the clinical trial of the drug known as BMS-986094 as a concern for safety.  

The drug maker has stopped the administration of the drug to about 30 patients who were a part of the Phase 2b study.  The heart failure occurred in a patient who received the highest daily dose of 200 miligrams.

Sonia Choi, a Bristol-Myers spokeswoman said, “Although the issue presented in a patient receiving that dose, it doesn’t preclude the possibility of issues with other doses.” Sonia also said, “At this point, we don’t know what the cause of the safety issue is. We are taking time to evaluate information on all patients receiving this compound.” 

The global pharma company has used acquisitions to get new experimental medicines as it aims to replace the loss of revenue from Plavix, a blood thinner which generated 33%  of 2011 sales. Bristol Myers is also competing with  other drug company Gilead Sciences Inc  to get clearance of the new generation of medicines to treat  the estimated 170 million patients with hepatitis C.

Bristol Myers Squibb is a pharmaceutical company formed through the merger of its predecessors Bristol-Myers and the Squibb Corporation. 

Share
Share

Featured Articles

Workplace Health Provision Easing Burden on Public Health

A Q&A with David Joerring, Founder & CEO of HealthKey, which connects health insurers and employers with digital health providers through API integrations

Healthcare Business roundup: Baxter, Sanofi & Eli Lilly

Baxter International to sell kidney care spin-off Vantive; Sanofi's consumer health unit ‘to be separated’; Eli Lilly to buy Morphic Holding for $3.2bn

Trane Technologies Helping US Hospitals Meet Climate Pledge

Christy Fetsch of Trane Technologies explains how the company is helping US hospitals meet White House sustainability pledges for US healthcare provision

Nestlé Health Science Targets Weight Loss Side-Effects

Medical Devices & Pharma

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Medical Devices & Pharma

WEF: Gender Health Gap 'Costs women 75mn years of Life'

Medical Devices & Pharma